Organogenesis Holdings Inc
ORGO
查看详细走势图
3.770USD
+0.060+1.62%
收盘 02/06, 16:00（美东）报价延迟15分钟
478.46M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.62%
5天
-5.75%
1月
-13.53%
6月
-16.22%
今年开始到现在
-27.22%
1年
+6.20%
查看详细走势图
TradingKey Organogenesis Holdings Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Organogenesis Holdings Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名69/392位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价8.50。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Organogenesis Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Organogenesis Holdings Inc亮点
亮点风险
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
业绩转亏
公司业绩转亏，最新年度亏损美元
估值低估
公司最新PE估值-50.37，处于3年历史低位
机构减仓
最新机构持股70.10M股，环比减少11.83%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值6.69K
分析师目标
根据
2
位分析师
强力买入
评级
8.500
目标均价
+129.11%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Organogenesis Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Organogenesis Holdings Inc简介
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
公司代码ORGO
公司Organogenesis Holdings Inc
CEOGillheeney (Gary S)
网址https://investors.organogenesis.com
相关品种
